Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application

Haematologica

Volumn 93, Issue 10, 2008, Pages 1535-1543

  Griffioen, Marieke ^a   Van Egmond, H M Esther ^a   Barnby Porritt, Helen ^b   Van Der Hoorn, Menno A W G ^a   Hagedoorn, Renate S ^a   Kester, Michel G D ^a   Schwabe, Nikolai ^b   Willemze, Roel ^a   Falkenburg, J H Frederik ^a   Heemskerk, Mirjam H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ProImmune Ltd   (United Kingdom)

Author keywords

Allogeneic stem cell transplantation; Gene therapy; Immunotherapy; T cell receptor

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; T LYMPHOCYTE;

CELLS, CULTURED; GENETIC VECTORS; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 54349105908     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13067     Document Type: Article

References (33)

1. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
2. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44.
3. Porter DL, Collins RH, Hardy C, Kernan AA, Drobyski WR, Giralt S, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214-21.
4. Marijt WAF, Heemskerk MHM, Kloosterboer FM, Goulmy E, Kester MGD, van der Hoorn MA, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003;100:2742-7.
5. Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MGD, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006;107:4954-60.
6. van Bergen CAM, Kester MGD, Jedema I, Heemskerk MHM, van Luxemburg-Heijs SA, Kloosterboer FM, et al. Multiple myeloma reactive T cells recognize an activation induced minor histocompatibility antigen encoded by the ATP dependent interferon responsive (ADIR) gene. Blood 2007;109:4089-96.
7. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2:512-9.
8. Heemskerk MHM, Hoogeboom M, de Paus RA, Kester MGD, van der Hoorn MA, Goulmy E, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 2003;102:3530-40.
9. Mommaas B, van Halteren AG, Pool J, van der Veken L, Wieles B, Heemskerk MHM, et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 2005;90:1415-21.
10. Heemskerk MHM, Hoogeboom M, Hagedoorn R, Kester MGD, Willemze R, Falkenburg JHF. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004;199:885-94.
11. Spierings E, Hendriks M, Absi L, Canossi A, Chhaya S, Crowley J, et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among Populations. PLoS Genet 2007;3:e103.
12. Riddell SR, Greenberg PD. T cell therapy of human CMV and EBV infection in immunocompromised hosts. Rev Med Virol 1997;7:181-92.
13. Einsele H, Hebart H. CMV-specific immunotherapy. Hum Immunol 2004;65:558-64.
14. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202:379-86.
15. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9.
16. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004;22:589-94.
17. Schambach A, Wodrich H, Hildinger M, Bohne J, Kräusslich HG, Baum C. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000;2:435-45.
18. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol 2000;165:6229-34.
19. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002;195:893-905.
20. Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77:5226-40.
21. Khan N, Hislop A, Gudgeon N, Cobbold M, Khanna R, Nayak L, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004;173:7481-9.
22. Hildinger M, Abel KL, Ostertag W, Baum C. Design of 5' untranslated sequences in retroviral vectors developed for medical use. J Virol 1999;73:4083-9.
23. Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Abina S, Fischer A. Gene therapy for severe combined immunodeficiency. Annu Rev Med 2005;56:585-602.
24. Recchia A, Bonini C, Magnani Z, Urbinati F, Sartori D, Muraro S, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 2006;103:1457-62.
25. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007;109:4698-707.
26. Heemskerk MHM, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MGD, et al. Efficiency of T cell receptor expression in dual specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007;109:235-43.
27. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008;118:294-305.
28. Engels B, Cam H, Schuler T, Indraccolo S, Gladow M, Baum C, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003;14:1155-68.
29. Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006;119:135-45.
30. Johnson LA, Heemskerk B, Powell DJ, Cohen CJ, Morgan RA, Dudley ME, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol 2006;177:6548-59.
31. Jorritsma A, Gomez-Eerland R, Dokter M, van de Kasteele W, Zoet YM, Doxiadis II, et al. Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood 2007;110:3564-72.
32. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 2006;66:8878-86.
33. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007;67:3898-903.